Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation

• US 6,894,021 B2
• Filed: 02/16/2001
• Issued: 05/17/2005
• Est. Priority Date: 02/17/2000
• Status: Expired due to Term

• Current Assignee: Gilead Palo Alto Incorporated (Gilead Sciences Inc.), University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: Gilead Palo Alto Incorporated (Gilead Sciences Inc.), University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Grant, Maria B., Belardinelli, Luiz
• Primary Examiner(s): BOWMAN, AMY HUDSON
• Application Number:
  US09/785,895
• Publication Number:
  US 20020002142A1
• Time in Patent Office: 1,551 Days
• Field of Search: 514/1, 514/262.1, 514/263.1, 514/263.2, 514/2, 514/44, 435/6, 435/7.2, 536/23.1, 536/24.5
• US Class Current: 514/1
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: G01N 2333/726 G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2500/10 involving cells

Abstract

This invention concerns methods for identifying A_2B adenosine receptor agonists and antagonists as well as methods for using A_2B adenosine receptor antagonists to treat cell proliferation orders mediated by the A_2B adenosine receptor.

Claims

1. A method for inhibiting the proliferation of mammalian retinal endothelial cells comprising administering a therapeutically effective amount of 3-N-propylxanthine to the mammalian retinal endothelial cells, whereby the proliferation of the mammalian retinal endothelial cells is inhibited.

2. The method of claim 1 wherein the 3-N-propylxanthine is administered in an amount ranging from about 1 microgram/kg to about 50 miligrams/kg.

3. The method of claim 1 wherein the 3-N-propylxanthine is administered in an amount ranging from about 1 microgram/kg to about 10 miligrams/kg.

4. The method of claim 1 wherein the 3-N-propylxanthine is administered by a method selected from the group consisting of orally, nasally, transdermally, by bolus, intravenously, in eye drops, by inhalation, and by using micropumps.

5. The method of claim 1 wherein the 3-N-propylxanthine is administered in eye drops.

6. The method of claim 1 wherein the mammal is a human.